The anti-RA mechanisms of ICA treatment may be mediated by ameliorating the levels of 23 metabolites, including 17a-estradiol, 5-methylcytidine, arachidonic acid, arginine, aspartic acid, cer(d18:0/18:0), citric acid, glutamine, and glycochenodeoxycholate; these metabolites are involved in 10 biological pathways related to alanine, aspartate and glutamate metabolism; arachidonic acid metabolism; citrate cycle; pyruvate metabolism; and glycolysis/gluconeogenesis pathways that are known to regulate the oxidative stress state and produce inflammatory effects. Here, CBLN1 is linked to rheumatoid arthritis.